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Abstract
Multiple Sclerosis (MS) patients present a decrease of antioxidants and neuroprotective and immunoregulatory
vitamins and an increase of total homocysteine (tHcy), cholesterol (CHL), HDL-cholesterol, and of cellular stress
markers, variably associated with the different phases of the disease. We compared the blood levels of uric acid,
folic acid, vitamins B12, A, and E, tHcy, CHL, HDL-cholesterol, and triglycerides in forty MS patients during a phase
of clinical inactivity with those of eighty healthy controls, matched for age and sex. We found higher levels of
tHcy (p = 0.032) and of HDL-cholesterol (p = 0.001) and lower levels of vitamin E (p = 0.001) and the ratio vitamin
E/CHL (p = 0.001) in MS patients. In conclusion, modifications of some biochemical markers of cell damage were
detected in MS patients during a phase of clinical inactivity.
Findings
A decrease of antioxidants [1], and neuroprotective [2,3]
and immunoregulatory vitamins [3,4] and an increase of
total homocysteine (t-Hcy) [5], cholesterol (CHL), HDL-
cholesterol [6], and of cellular stress markers [7,8] were
reported in patients affected by multiple sclerosis (MS).
These changes are regarded as markers of autoimmunity
or neurodegeneration. Recently, in view of the unrelia-
bility of these results, mainly due to the heterogeneity of
the samples investigated, attention has focused on clini-
cal relapse; and active MS has proved to be associated
w i t had e c r e a s eo fu r i ca c i d( U A )a n da ni n c r e a s eo f
CHL and stress markers [1,6,8]. To characterize the bio-
chemical status of MS during a phase of clinical inactiv-
ity, we compared the blood levels of UA, folic acid (FA),
vitamins B12, A, and E, t-Hcy, CHL, HDL-cholesterol,
and triglycerides (TG) in stable MS patients with those
of healthy controls.
Forty consecutive MS patients with relapsing-remitting
or secondary-progressive courses and in a phase of clini-
cal inactivity, participated in the study. They had been
free of steroids for at least one month and of immuno-
modulatory or immunosuppressive drugs for at least
two months. The study protocol was approved by the
local Ethics Committee. Formal written consent was
obtained from each patient. Two venous blood samples
were obtained from patient with a time lag of one
month in between. A number of healthy individuals
were enrolled after their formal written consent. Con-
trols were matched for age (+2 years) and gender to the
patients in the ratio of two controls for each case. A
venous blood sample was obtained from each control.
Pregnant women, habitual smokers, alcohol drinkers,
and consumers of vitamins-rich products were excluded.
Among the cases, individuals with other disorders in
addition to MS were also excluded. Venipuncture, using
masked materials, was performed in fasting subjects
who on the two previous days had avoided certain
habits (alcohol consumption, cigarettes, cigars, and pipe
smoking) and foods (red meat, liver, kidney, spleen, fish
and sea food, salted food and fat cheese, sweets, grapes,
bananas, figs, persimmons, cherry, nuts, and the like)
which could have modified the concentration of the
molecules to be detected. The Ubbink method was used
to establish plasma levels of tHcy [9]. Competitive mag-
netic separation on a Technicon Immuno autoanalyser
was used for serum FA and vitamin B12 assays. High-
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cially available enzymatic colorimetric tests were used
for UA, CHL, HDL-cholesterol, and TG assays (Roche
Diagnostics GmbH, Mannheim). The vitamin E/CHL
ratio was calculated. Mean differences in normally dis-
tributed data between cases and controls were analysed
by Student’s t test. As tHcy, FA, UA, vitamin A, and
vitamin E concentrations were not uniformly distribu-
ted, median values and the Mann-Whitney U test were
used for comparison of the patient and control groups.
To increase dosage reliability; patients had two different
venipunctures and their mean value was used for
calculations.
We included 40 MS patients and 80 healthy controls.
The patients’ median age was 39.5 years (range 16 - 58);
twelve were male; mean MS duration was 11.95 ± 9.28
years; median EDSS was 3.0 (range 1.0 - 6.0); mean
M S S Sw a s3 . 9 5±1 . 9 5 ;2 8p a t i e n t sh a dar e l a p s i n g -
remitting course and 12 had a secondary-progressive
course. Because of the matching criteria, the control
group had the same distribution for age (median age:
38.5 years; range 16 - 56) and gender. Table 1 shows
the results obtained for each molecule comparing the
cases and the control groups. The concentration of UA,
FA, TG, and vitamin A was similar between patients
and controls. Vitamin B12 and CHL concentration was
higher in MS patients, but the difference between the
two groups did not reach statistical significance. The
concentration of HDL-cholesterol and Hcy was higher
in the MS group, while the concentration of vitamin E
and the ratio of vitamin E and CHL (E/CHL) were
lower in the MS group; these differences were statisti-
cally significant.
T h i ss t u d ys h o w st h a tt h eM Sp a t i e n t si nap h a s eo f
clinical inactivity presented modifications of some bio-
chemical markers of cell damage. The study’sm a i n
weakness is its limited sample size and it must therefore
be regarded as preliminary to larger investigations. How-
ever, the study also has some strong points: it restricted
inclusion to patients in a clinically stable phase, it
excluded primary progressive MS patients, and on the
days preceding the venipunctu r ei te x c l u d e dt h ei n t a k e
of foods or substances that might have modified the
concentration of the molecules studied. We found that
the MS patients in a phase of clinical stability had
higher blood levels of tHcy and HDL-cholesterol and
lower blood levels of vitamin E and the E/CHL ratio.
The increased levels of tHcy, that we found in our
patients, were consistent with those of previous studies
performed in MS patients outside relapse [5]. The
meaning of the increase, which damaged the folding of
proteins by increasing the cleavage of disulphide bridges
and was targeted to generate free radicals, is uncertain
and requires specific study. Our data agree with those
reported elsewhere that tHcy increase was paralleled not
by a decrease of vitamin B12 and FA, as usually
reported for other disorders, but by normal or increased
values of both vitamins [5]. This observation also
requires “ad hoc” studies. The increased concentration
of HDL-cholesterol in a stable phase of the disease
could counteract the increased concentration of choles-
terol that occurs in the course of a relapse and ensure
that it reaches the liver [10]. Increased values of total
and HDL - cholesterol were reported in a study aimed
at assessing the correlation between blood CHL and
MRI activity after a clinical episode suggesting MS [6].
The decrease of the concentration of vitamin E, the
major hydrophobic chain-breaking antioxidant, confirms
the possible involvement of this vitamin in MS pathol-
ogy: vitamin E levels are decreased in the demyelination
plaques of MS brains, and vitamin E levels and E/CHL
ratios are lower in the serum of MS patients [2]. How-
ever, serum vitamin E is not a marker of clinical activity
because it is not paralleled by a similar low concentra-
tion in the CSF or by a reduction of the [vitamin ECSF]/
[vitamin Eserum] ratio. Our data could indicate that vita-
min E was consumed to counterbalance MS chronic
neurodegeneration.
We observed no differences as regards UA, FA, vita-
min A, vitamin B12, CHL, and TG between MS patients
in a phase of clinical inactivity and healthy controls,
which means that they are unlikely to be involved in the
biochemical processes taking place during this phase of
MS. However, the role of UA concentration in MS out-
side a clinical relapse remains controversial. Some
Table 1 Comparison of Blood Lipids, total Homocysteine,
Uric Acid and Vitamins concentration in subjects with a
Multiple Sclerosis and in healthy controls
Molecule
a Patients Controls P°
Vitamin B12 666.42 ± 354.16 493.70 ± 229.16 0.058
Folic acid 7.3 (2.8, 25.0) 5.9 (1.2, 16.0) 0.196
Uric acid 4.3 (2.8, 5.9) 4.1 (2.1, 7.3) 1.000
Homocysteine 9.3 (4.0, 86.5) 6.3 (3.2, 15.0) 0.032
Vitamin A 0.3 (0.1, 0.7) 0.4 (0.1, 2.4) 0.149
Vitamin E 12.0 (5.4, 26.5) 22.5 (1.9, 70.2) 0.001
Cholesterol 187.70 ± 40.30 169.07 ± 35.18 0.071
HDL-cholesterol 61.42 ± 14.85 50.05 ± 10.81 0.001
Triglyceride 92.82 ± 46.72 82.35 ± 44.52 0.401
E/CHL 0.07 ± 0.04 0.15 ± 0.08 0.001
*Vitamin B12 (pg/ml), total Cholesterol (mg%), HDL-cholesterol (mg%) and
Triglyceride (mg %) had a normal distribution; mean values and standard
deviation are reported. Folic acid (ng/ml), Uric acid (mg %), total
Homocysteine (μmol/L), vitamin A (mgr/L), and vitamin E (mgr/L) had not a
normal distribution; median values, minimum and maximum are reported.
° Student “t test” was used to calculate statistical significativity for vitamin
B12, cholesterol, HDL-cholesterol, triglycerid, and E/CHL ratio. Mann-Whitney U
test was used to calculate statistical significativity for folic acid, uric acid,
homocysteine, vitamin A, and vitamin E.
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ing with our results; others found an increase of UA
both in serum and in cerebrospinal fluid (CSF) [1,7,11].
These conflicting results could be explained by differ-
ences in the populations studied or by different detec-
tion methods and they require further investigation for
a better understanding of the role of UA in the bio-
chemical changes occurring in the course of MS.
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